Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin’s lymphoma

IntroductionLymphodepleting chemotherapy (LDC) is critical to CAR T-cell expansion and efficacy. Despite this, there is not a consensus in the literature regarding the optimal LDC regimen, including dose and frequency.MethodsWe retrospectively reviewed consecutive patients at a single institution th...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Frontiers in Immunology
المؤلفون الرئيسيون:	David G. Frame, Marcus Geer, Salena Kasha, Denise Markstrom, Gianni Scappaticci, Tate Feeney, Andrew Hayduk, Hilary M. Mansoor, Avery Oberfeld, Hannah D’Antonio, Sarah Anand, Sung Won Choi, John Maciejewski, Attaphol Pawarode, Mary Mansour Riwes, Muneesh Tewari, John Magenau, Monalisa Ghosh
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Frontiers Media S.A. 2024-06-01
الموضوعات:	CAR T-cell non-hodgkin’s lymphoma lymphodepletion CRS ICANS
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1403145/full

مواد مشابهة

Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel
حسب: Guido Ghilardi, وآخرون
منشور في: (2024-04-01)

Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle
حسب: Benno Lickefett, وآخرون
منشور في: (2023-12-01)

A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome
حسب: Omar H. Butt, وآخرون
منشور في: (2023-02-01)

Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine?
حسب: Dimitrios Filioglou, وآخرون
منشور في: (2023-11-01)

Selective CD28 blockade impacts T cell differentiation during homeostatic reconstitution following lymphodepletion
حسب: Jakob G. Habib, وآخرون
منشور في: (2023-01-01)

Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies
حسب: Belén Sierro-Martínez, وآخرون
منشور في: (2025-08-01)

Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy
حسب: Beatrice Manghisi, وآخرون
منشور في: (2025-04-01)

Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome
حسب: Tim Lakomy, وآخرون
منشور في: (2023-02-01)

The Kinetics of Inflammation-Related Proteins and Cytokines in Children Undergoing CAR-T Cell Therapy—Are They Biomarkers of Therapy-Related Toxicities?
حسب: Paweł Marschollek, وآخرون
منشور في: (2024-07-01)

Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience
حسب: Aaron Trando, وآخرون
منشور في: (2024-12-01)

Building safety into CAR-T therapy
حسب: Daniel T. Peters, وآخرون
منشور في: (2023-12-01)

Harnessing Biomaterials for Safeguarding Chimeric Antigen Receptor T Cell Therapy: An Artful Expedition in Mitigating Adverse Effects
حسب: Zhaozhao Chen, وآخرون
منشور في: (2024-01-01)

Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment
حسب: Franziska Marquard, وآخرون
منشور في: (2023-11-01)

A lymphodepleted non‐human primate model for the assessment of acute on‐target and off‐tumor toxicity of human chimeric antigen receptor‐T cells
حسب: Shigeki Yagyu, وآخرون
منشور في: (2021-01-01)

Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients
حسب: Yunju Ma, وآخرون
منشور في: (2023-04-01)

Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
حسب: Robert C. Sterner, وآخرون
منشور في: (2022-08-01)

Toxicities associated with lymphoma-targeting bispecific antibodies—a review
حسب: Christopher Doig, وآخرون
منشور في: (2025-07-01)

Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities
حسب: Avis Harden, وآخرون
منشور في: (2020-08-01)

Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma
حسب: Castaneda-Puglianini O, وآخرون
منشور في: (2021-08-01)

CD19 -targeted CAR T therapy treating hematologic malignancies: hidden danger is the next neighbor to security?
حسب: Xueshuai Ye, وآخرون
منشور في: (2025-03-01)

PD-1 inhibition for relapse after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome
حسب: John M. Magenau, وآخرون
منشور في: (2025-08-01)

Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy
حسب: Tobias Moser, وآخرون
منشور في: (2021-10-01)

Advances in research on factors affecting chimeric antigen receptor T‐cell efficacy
حسب: Delian Zhou, وآخرون
منشور في: (2024-06-01)

IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer
حسب: Jing Guo, وآخرون
منشور في: (2024-05-01)

Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma
حسب: Semira Sheikh, وآخرون
منشور في: (2022-02-01)

Change in Neurocognitive Function in Patients Who Receive CAR-T Cell Therapies: A Steep Hill to Climb
حسب: Evlampia Strongyli, وآخرون
منشور في: (2024-05-01)

Systemic depletion of lymphocytes following focal radiation to the brain in a murine model
حسب: Anna F. Piotrowski, وآخرون
منشور في: (2018-07-01)

European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring
حسب: Biagio De Angelis, وآخرون
منشور في: (2025-04-01)

Predictors of Neurotoxicity in a Large Cohort of Italian Patients Undergoing Anti‐CD19 Chimeric Antigen Receptor (CAR) T‐Cell Therapy
حسب: Anna Modoni, وآخرون
منشور في: (2025-09-01)

Case Report: Severe HHV-6-related encephalitis following anti-CD19 CAR-T therapy with no evidence of HHV-6 reactivation in transduced CAR-T cells
حسب: Nina Marie Birk, وآخرون
منشور في: (2025-09-01)

CAR-T Cells for the Treatment of Central Nervous System Tumours: Known and Emerging Neurotoxicities
حسب: Leonardo Palazzo, وآخرون
منشور في: (2024-11-01)

Diagnostic therapeutic assistance pathway (PDTA) of type 2 chronic rhinosinusitis
حسب: Frank Rikki Canevari, وآخرون
منشور في: (2023-09-01)

Chimeric Antigen Receptor (CAR) T-Cell Therapy Use in Patients with Multiple Myeloma and Kidney Failure on Maintenance Hemodialysis: A Report of 2 Cases
حسب: Wai Lun Will Pak, وآخرون
منشور في: (2024-08-01)

Immunoenhancing properties of the anti-tumor effects of adoptively transferred T cells with chemotherapeutic cyclophosphamide by co-administration of bone marrow cells
حسب: Mohamed L. Salem, وآخرون
منشور في: (2015-10-01)

Management strategies for CAR-T cell therapy-related toxicities: results from a survey in Greece
حسب: Eleni Gavriilaki, وآخرون
منشور في: (2025-05-01)

Patient reported outcome measures (PRO) in colorectal surgery
حسب: Kathia E. Nitsch, BS, وآخرون
منشور في: (2024-06-01)

Muscarinic acetylcholine receptor activated effectors in principal neurons of the rat basolateral amygdala
حسب: Todd J. Sahagian, وآخرون
منشور في: (2025-07-01)

Editorial: Novel insights into CAR T-cell associated neurotoxicity
حسب: Stella Bouziana
منشور في: (2023-11-01)

Articular Eminence Inclination between Croatian and American Skulls
حسب: Josip Kranjčić, وآخرون
منشور في: (2025-01-01)

Mechanisms and management of CAR T toxicity
حسب: Christopher J. Ferreri, وآخرون
منشور في: (2024-05-01)